Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
and you are
between 18 and 55
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

A phase IV study with the primary goal to optimize therapy of adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma (LBL) by dose and time intensive, pediatric based chemotherapy, risk adapted stem cell transplantation (SCT) and minimal residual disease (MRD) based individualised and intensified therapy. Study will further evaluate the role of asparaginase intensification, the extended use of rituximab and the use of nelarabine as consolidation therapy in T-ALL in a phase III-part of the study. Furthermore two randomisations will focus on the role of central nervous system (CNS) irradiation in combination with intrathecal therapy versus intrathecal therapy only in B-precursor ALL/LBL and the role of SCT in high-risk patients with molecular complete remission. Finally a new, dose reduced induction therapy in combination with Imatinib will be evaluated in Ph/BCR-ABL positive ALL.

Provided treatments

  • Drug: Rituximab
  • Drug: Nelarabine
  • Drug: PEG-Asparaginase
  • Procedure: Cranial irradiation
  • Drug: Imatinib
  • Drug: Idarubicin
  • Drug: Dexamethasone
  • Drug: Cyclophosphamide
  • Drug: Fludarabine
  • Drug: Vincristine
  • Drug: Mercaptopurine
  • Drug: VP16
  • Drug: Daunorubicin (DNR)
  • Drug: Methotrexate
  • Procedure: Stem cell transplantation
  • Drug: Cytarabine
  • Drug: Vindesine
  • Drug: Adriamycin
  • Drug: Prednisolone
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02881086. The sponsor of the trial is Goethe University and it is looking for 900 volunteers for the current phase.
Official trial title:
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients